Physician profile
Julie Yip
NPI 1053670646
$8,324.84
in general payments reported to CMS, 2019-2025
30 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $345 · 2021: $48.17 · 2022: $1,702 · 2023: $1,269 · 2024: $1,741 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.49 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,770.27 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,268.25 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,154.76 | 2019-2025 | Enbrel, Evenity, Otezla |
| Janssen Biotech, INC. | $752.49 | 2019-2025 | Tremfya |
| Pfizer INC. | $533.21 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $432.43 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $415.81 | 2019-2025 | Taltz, Zepbound |
| Genzyme Corporation | $305.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $227.37 | 2022-2025 | Orencia |
| Radius Health, INC. | $214.42 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.41 | 2019-2024 | Cyltezo |
| Glaxosmithkline, LLC. | $151.88 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $148.44 | 2022-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $108.71 | 2019-2025 | |
| Genentech USA, INC. | $107.20 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.85 | 2019 | |
| Scilex Pharmaceuticals INC. | $60.69 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $60.26 | 2022-2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $53.80 | 2024 | Idacio |
| Sobi, INC | $49.23 | 2024 | |
| Merck Sharp & Dohme LLC | $44.58 | 2019-2020 | |
| Organon LLC | $40.27 | 2022-2025 | Hadlima |
| Sandoz INC. | $32.65 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $31.68 | 2020 | |
| Hikma Pharmaceuticals USA | $16.04 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.04 | 2019 | |
| Biocon Biologics INC | $15.24 | 2024 | Hulio |
| Janssen Pharmaceuticals, INC | $15.14 | 2019 | |
| Horizon Therapeutics Plc | $12.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.